Corbus Pharmaceuticals Holdings (STU:3371) Other Stockholders Equity: €-0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:3371 Corbus Pharmaceuticals Holdings Inc STU:3371
37 GF Score
Price €7.89
Valuation Significantly Overvalued
! 1 Warning Sign
View Full Analysis

What is Corbus Pharmaceuticals Holdings Other Stockholders Equity?

Corbus Pharmaceuticals Holdings STU:3371 +2.67% 37 Other Stockholders Equity is €-0.00 Mil as of Mar. 2026. GuruFocus rates STU:3371 with a GF Score™ of 37/100 (Significantly Overvalued). The stock has 1 warning sign investors should review.

Corbus Pharmaceuticals Holdings's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €-0.00 Mil.

Corbus Pharmaceuticals Holdings's quarterly Other Stockholders Equity increased from Sep. 2025 (€0.00 Mil) to Dec. 2025 (€0.00 Mil) but then declined from Dec. 2025 (€0.00 Mil) to Mar. 2026 (€-0.00 Mil).

Corbus Pharmaceuticals Holdings's annual Other Stockholders Equity increased from Dec. 2023 (€0.00 Mil) to Dec. 2024 (€0.00 Mil) but then declined from Dec. 2024 (€0.00 Mil) to Dec. 2025 (€0.00 Mil).

Corbus Pharmaceuticals Holdings Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Corbus Pharmaceuticals Holdings's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corbus Pharmaceuticals Holdings Other Stockholders Equity Chart

Corbus Pharmaceuticals Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Corbus Pharmaceuticals Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.00
STU:3371
37GF Score
Corbus Pharmaceuticals Holdings Inc STU:3371
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corbus Pharmaceuticals Holdings Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €-0.00 Mil mean?
Corbus Pharmaceuticals Holdings (STU:3371) has a Other Stockholders Equity of €-0.00 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Corbus Pharmaceuticals Holdings and its competitors.
Is Corbus Pharmaceuticals Holdings' Other Stockholders Equity too high?
Corbus Pharmaceuticals Holdings' current Other Stockholders Equity is €-0.00 Mil. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Other Stockholders Equity compare to PRQR and NRXP?
Corbus Pharmaceuticals Holdings' Other Stockholders Equity of €-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Corbus Pharmaceuticals Holdings and its competitors. Corbus Pharmaceuticals Holdings's current Other Stockholders Equity is €-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings (STU:3371) is currently considered Significantly Overvalued. The current Other Stockholders Equity is €-0.00 Mil. Corbus Pharmaceuticals Holdings' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (STU:3371), the current Other Stockholders Equity is €-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corbus Pharmaceuticals Holdings Business Description

Other Exchanges CRBP:USA0SZI:UK
Address 500 River Ridge Drive, Norwood, MA, USA, 02062
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
37GF Score

Get the complete analysis for STU:3371

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.89
Price